Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yash Ashara

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Cancer Treatment and Research Communications|August 2, 2023
Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief reportAakash Desai, Sagar Rakshit, Radhika Bansal, et al.
Clinical Lung Cancer|October 25, 2023
Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung CancerAakash Desai, Caleb J Smith, Yash Ashara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyAmin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Cancer Treatment and Research Communications|August 2, 2023
Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief reportAakash Desai, Sagar Rakshit, Radhika Bansal, et al.
Clinical Lung Cancer|October 25, 2023
Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung CancerAakash Desai, Caleb J Smith, Yash Ashara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyAmin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.
Pageof 1